IL-4R-alpha
Assets acting on this target.
- Class
- Anti-IL-4Ralpha monoclonal antibody
- Notes
- original target text: IL-4 receptor alpha
Interleukin-4 receptor alpha (IL-4Rα) is a cell-surface protein that serves as the shared signaling subunit for two related cytokines, interleukin-4 (IL-4) and interleukin-13 (IL-13). These cytokines are central drivers of what immunologists call type 2 inflammation, a branch of the immune response involved in defense against parasites but also implicated in allergic disease. By binding IL-4Rα, an antibody can block signaling from both cytokines simultaneously rather than neutralizing just one, which matters because IL-4 and IL-13 have overlapping but non-identical roles in promoting antibody class-switching to immunoglobulin E, recruitment of eosinophils, mucus overproduction, and tissue remodeling seen in allergic conditions. This dual-blockade rationale distinguishes IL-4Rα-targeting antibodies from agents that inhibit only IL-13 or only IL-4, since either cytokine alone can partially sustain the inflammatory pathway if the other is left unopposed. Conditions where this mechanism is broadly relevant include atopic dermatitis, asthma with an allergic or eosinophilic component, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis, all of which are driven substantially by type 2 immune signaling. Modulating this target is a strategy for reducing chronic allergic and eosinophilic inflammation across multiple organ systems by acting on a single upstream convergence point rather than on many downstream mediators individually.
By indication
IL-4R-alpha drugs compared
11 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| dupilumabDupixent | Regeneron Pharmaceuticals, Sanofi | monoclonal antibody | Approved | Approved in Asthma; Approved in Atopic Dermatitis; Approved in Chronic Obstructive Pulmonary Disease; Approved in Chronic Spontaneous Urticaria; Approved in Eosinophilic Esophagitis; Approved in Prurigo Nodularis |
| GS101 | Jiangsu Genscend Biopharmaceutical | monoclonal antibody (biosimilar) | Phase 3 | Phase 3 in Atopic Dermatitis |
| Manfidokimab | Akeso | monoclonal antibody | Phase 3 | Phase 3 in Atopic Dermatitis |
| QL2108 | Qilu Pharmaceutical | monoclonal antibody (biosimilar) | Phase 3 | Phase 3 in Atopic Dermatitis |
| Rademikibart | Connect Biopharma, Simcere Pharmaceutical | monoclonal antibody | Phase 3 | Phase 3 in Asthma; Phase 3 in Atopic Dermatitis; Phase 2 in Chronic Obstructive Pulmonary Disease |
| SHR-1819 | Jiangsu Hengrui Pharmaceuticals | monoclonal antibody | Phase 3 | Phase 3 in Atopic Dermatitis |
| SSGJ-611 | Sunshine Guojian Pharmaceutical | monoclonal antibody | Phase 3 | Phase 3 in Atopic Dermatitis |
| stapokibart | Aeira Pte. Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Keymed Biosciences | monoclonal antibody | Phase 3 | Phase 3 in Atopic Dermatitis; Phase 3 in Prurigo Nodularis; Phase 2/3 in Asthma; Phase 2/3 in Chronic Obstructive Pulmonary Disease |
| Telikibart | Genrix Bio | monoclonal antibody | Phase 3 | Phase 3 in Atopic Dermatitis |
| APG808 | AbbVie, Apogee Therapeutics, Paragon Therapeutics | monoclonal antibody | Phase 1 | Not recorded |
| CKD-706 | Chong Kun Dang Pharmaceutical | monoclonal antibody (biosimilar) | Phase 1 | Phase 1 in Atopic Dermatitis |